Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 07/29 10:14:59 pm
79.47 USD   -2.18%
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/28 GILEAD SCIENCES : Anger At Huge Price Tag for Life-Saving Medicine
News SummaryMost relevantAll newsSector news 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/28 GILEAD SCIENCES : to Release Second Quarter 2016 Financial Results on Monday, Ju..
07/28 GILEAD SCIENCES : Odefsey® Emtricitabine, Rilpivirine, Tenofovir Alafenamide Mee..
07/28 GILEAD SCIENCES : Anger At Huge Price Tag for Life-Saving Medicine
07/26 TEXAS INSTRUMENTS : Gilead Sciences and McDonald's slip; Texas Instruments rises
07/26 MARKETS RIGHT NOW : US stocks turn lower in midday trade
07/26 NASDAQ 100 MOVERS : Gild, txn
07/26 S&P 500 MOVERS : Cnc, txn
07/26 GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
More news
Sector news : Bio Therapeutic Drugs
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02:56a Through The End Of July, Our Portfolio Is Up More Than 12% For 2016
07/30 RESURGENCE OF LANNETT : A Growing Opportunity
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
07/29 Updating My Fair Value On Gilead Sciences
07/29 CNBC : Medivation sets mid-August deadline; SNY, PFE, GILD, CELG in play
Financials ($)
Sales 2016 30 512 M
EBIT 2016 20 315 M
Net income 2016 14 598 M
Debt 2016 5 857 M
Yield 2016 2,33%
P/E ratio 2016 7,45
P/E ratio 2017 7,06
EV / Sales 2016 3,66x
EV / Sales 2017 3,54x
Capitalization 105 840 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 $
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-21.46%105 840
AMGEN, INC.5.98%129 232
ACTELION LTD23.14%20 223
More Results